Merrimack's Prospects Dim As MM-141 Fails Pancreatic Cancer Phase II Trial
Merrimack Pharmaceuticals has ended development of its experimental treatment for pancreatic cancer after it failed to meet the main and secondary goals in a mid-stage trial.
You may also be interested in...
CEO David Meek Says Ipsen has more than $1bn for M&A use to expand its product line in oncology, neuroscience and rare diseases.
Evotec’s multimodality approach to drug discovery landed the biotech two new discovery collaborations this week, underscoring its emphasis on patient-driven data.
Novo Nordisk and Evotec will identify and develop novel drugs for treating chronic kidney disease, using datasets of CKD patients provided by the Danish group and from other sources.